Wenbin Qian

26PUBLICATIONS
111CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersArtificial life and complex adaptive systemsRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Oct 15, 2026
Next-generation natural killer cell therapy: bench to bedside and beyond.

|Jul 22, 2026
Long-term Follow-up of Third-generation Anti-CD30 CAR T-cell Therapy in Relapsed/Refractory CD30+ Lymphomas: A Single-Arm, Multicenter, Phase I/II Trial.

|Jun 08, 2026
Integrated Genomic and Tumor Microenvironment Subtyping Improved Risk Stratification in Primary Central Nervous System Lymphoma.

|Sep 08, 2025
CD33KO-CD33-mesothelin Loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia.

Yao Wang, Xiujuan Zheng, Zhiqian Wang

|Aug 15, 2025
STRaM: A genetic framework for improved cell product provenance for research and clinical translations.

Binglin Li, Chi Le, Wen Lei

|Apr 18, 2025
Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial.

Wen Lei, Hui Liu, Wenhai Deng

Pageof 5

Frequent Collaborators

5 joint publications

Wenhai Deng

4 joint publications

Aibin Liang

3 joint publications

Hui Liu

2 joint publications

Yang Xu